HIGHLIGHTS
- who: JHEOR and colleagues from the ICON plc, Vancouver, Canada Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK have published the article: A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma, in the Journal: (JOURNAL)
- what: The aim of this study was to develop a cost-effectiveness model comparing brentuximab vedotin with conventional chemotherapies for patients with R/R sALCL, from a UK National Health Service (NHS) perspective. At the time of the analysis, with a median observation time of 33.4 months (range 0.8 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.